Stifel Financial Corp Sells 6,893 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Stifel Financial Corp lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 20.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,723 shares of the company's stock after selling 6,893 shares during the quarter. Stifel Financial Corp's holdings in IDEXX Laboratories were worth $11,048,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC raised its holdings in shares of IDEXX Laboratories by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock worth $948,279,000 after buying an additional 37,734 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of IDEXX Laboratories by 2.5% during the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock valued at $675,259,000 after acquiring an additional 34,305 shares during the period. Invesco Ltd. boosted its stake in shares of IDEXX Laboratories by 6.8% in the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock valued at $479,999,000 after purchasing an additional 74,324 shares in the last quarter. Norges Bank bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $412,258,000. Finally, American Century Companies Inc. increased its position in shares of IDEXX Laboratories by 30.9% during the 4th quarter. American Century Companies Inc. now owns 809,814 shares of the company's stock worth $334,810,000 after purchasing an additional 191,385 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 12th. Morgan Stanley dropped their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Barclays boosted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Finally, Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $523.75.

IDEXX Laboratories Trading Up 3.4 %

IDXX stock traded up $14.35 during midday trading on Thursday, reaching $440.98. The stock had a trading volume of 746,755 shares, compared to its average volume of 629,776. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88. The firm has a market cap of $35.74 billion, a price-to-earnings ratio of 41.33, a PEG ratio of 3.41 and a beta of 1.50. The business has a fifty day simple moving average of $420.23 and a two-hundred day simple moving average of $429.89.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.